ATF2 contributes to cisplatin resistance in non‐small cell lung cancer and celastrol induces cisplatin resensitization through inhibition of JNK/ATF2 pathway
Marco Lo Iacono(University of Turin), Giorgio V. Scagliotti(University of Turin)
Cited by 56
Related Papers
The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies
|The Oncologist|2009|692
Aurora Kinase A expression is associated with lung cancer histological-subtypes and with tumor de-differentiation
|Journal of Translational Medicine|2011|61
Molecular Mechanisms of Mitotane Action in Adrenocortical Cancer Based on In Vitro Studies
|Cancers|2021|29
Targeting ER stress in adrenocortical carcinoma: Celastrol as a novel therapeutic candidate
|Biomedicine & Pharmacotherapy|2026|0